Charles Schwab Investment Management Inc. Has $20.96 Million Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Charles Schwab Investment Management Inc. increased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 1.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,028,462 shares of the company’s stock after acquiring an additional 12,652 shares during the period. Charles Schwab Investment Management Inc. owned about 0.71% of Denali Therapeutics worth $20,960,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Fisher Asset Management LLC boosted its position in shares of Denali Therapeutics by 44.8% during the 4th quarter. Fisher Asset Management LLC now owns 792,499 shares of the company’s stock worth $16,151,000 after acquiring an additional 245,168 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Denali Therapeutics during the 4th quarter worth approximately $514,000. Y Intercept Hong Kong Ltd boosted its position in shares of Denali Therapeutics by 160.5% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 36,006 shares of the company’s stock worth $734,000 after acquiring an additional 22,183 shares in the last quarter. State of New Jersey Common Pension Fund D boosted its position in Denali Therapeutics by 11.3% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 86,243 shares of the company’s stock valued at $1,758,000 after buying an additional 8,760 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Denali Therapeutics by 0.3% in the fourth quarter. Rhumbline Advisers now owns 190,390 shares of the company’s stock valued at $3,880,000 after buying an additional 497 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 29,266 shares of Denali Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the completion of the sale, the chief executive officer now directly owns 260,721 shares of the company’s stock, valued at approximately $5,271,778.62. The trade was a 10.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,940 shares of company stock valued at $973,442. Corporate insiders own 7.90% of the company’s stock.

Denali Therapeutics Stock Up 2.1 %

Shares of NASDAQ DNLI opened at $14.82 on Thursday. Denali Therapeutics Inc. has a twelve month low of $14.01 and a twelve month high of $33.33. The firm has a fifty day simple moving average of $19.91 and a 200 day simple moving average of $23.77. The company has a market capitalization of $2.15 billion, a PE ratio of -5.37 and a beta of 1.46.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08. As a group, equities analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on DNLI shares. Robert W. Baird started coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 target price on the stock. William Blair restated an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Morgan Stanley started coverage on shares of Denali Therapeutics in a research report on Friday, March 7th. They issued an “overweight” rating and a $33.00 target price on the stock. The Goldman Sachs Group cut their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Finally, HC Wainwright raised their target price on shares of Denali Therapeutics from $80.00 to $87.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.20.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.